Bajaj Healthcare Ltd.
Fundamentals
- Market cap
- ₹1,018 cr
- P/E
- 47.77×
- ROE
- 8.47%
- Debt / equity
- 0.48
- Div yield
- 0.48%
- 52-week range
- 272.45 — 552.55
Analysis — the numbers vs the call
- Bajaj Healthcare's steady quarter, muddled peptide timeline
Q1 revenue up 11% but management's shifting guidance on the peptide plant erodes confidence in its ₹900-1,000 crore revenue target.
Company snapshot
Bajaj Healthcare Ltd.
Pharmaceuticals
₹1,295 cr
P/E 60.79×
Latest quarter · Jun 2026
Sales₹166 cr
Net profit₹14 cr
Op. margin+17.4%
EPS₹4.13
Strength & growth
Debt / equity0.48×
Current ratio1.78×
Sales CAGR+3.4%
The timeline — 2 notes on Bajaj Healthcare Ltd.
July 2026
- 20 Jul 26 · 8:51 PM IST Brief Brief · Earnings · Small cap
Bajaj Healthcare Q1 revenue up 11%; results reiterate known numbers
Domestic API sales jumped 27% but exports slipped. The press release adds nothing new beyond the board outcome.
- 20 Jul 26 · 7:45 PM IST Brief Brief · Earnings · Small cap
Bajaj Healthcare logs 11% revenue growth in Q1, PBT up 13%
Standalone revenue from continuing operations rose to ₹165.63 crore in the June 2026 quarter; board also approved continuation of independent director beyond age 75.